Effect of Saxagliptin (DPP-4 Inhibitor) on Endothelial Progenitor Cells (EPCs) as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 26 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 26 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association